AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06486337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMOP±R
Description: Drug: Mitoxantrone hydrochloride liposome Mitoxantrone hydrochloride liposome (18 mg/m\^2) on day 1, every 4 weeks; Drug: Cyclophosphamide Cyclophosphamide(750 mg/m\^2) on day 1, every 4 weeks; Drug: Vincristine Vincristine (1.4mg/ m2，Max dose 2mg) will be administered on day 1(Or at the discretion of the investigator, use other vinblastine drugs with the same mechanism, such as vindesine 2-3 mg/m2 on day 1), every 4 weeks; Drug: Prednisone Prednisone (100 mg) will be taken orally from day 1-5(Or equivalent dose of dexamethasone at 15mg), every 4 weeks; Drug: Rituximab Rituximab (375mg/m\^2) on day 0, every 4 weeks, only with CD20-positive lymphomas are evaluated by the investigator.
Study NCT04849299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + cyclosporine
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered simultaneously on Day 7 Other Names: AT-527 is also known as R07496998
Study NCT04849299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 550 mg + cyclosporine
Description: 550 mg AT-527 alone on Day 1 and 550 mg AT-527 plus 600 mg cyclosporine administered on Day 7 (with dosing offset by 2 hrs) Other Names: AT-527 is also known as R07496998
Study NCT05580835 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET MRI with PSMA
Description: A whole-body PET using PSMA as a radiotracer associated to an upper abdomen MRI with gadoxetic acid as contrast agent
Study NCT05643755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative image-based education
Description: Intervention group: education handout containing pictographic and written education material on wound appearance following primary closure after Mohs Micrographic Surgery (MMS) or Wide Local Excision (WLE)
Study NCT06319157 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: minimal access breast reconstruction with a latissimus dorsi muscle flap
Description: minimal access breast reconstruction with a latissimus dorsi muscle flap
Study NCT06319157 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: conventional breast reconstruction with a latissimus dorsi muscle flap
Description: conventional breast reconstruction with a latissimus dorsi muscle flap
Study NCT04773067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-612
Description: Around 3300 adult subjects and 330 adolescent subjects will receive 2 doses of 100 µg UB-612 vaccine. The subjects will be invited to have the 3rd dose after unblinded.
Study NCT04773067 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Around 550 adult subjects and 55 adolescent subjects will receive 2 doses of normal saline 0.9%.
Study NCT05518695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2022
Description: Eight healthy subjects are planned to be enrolled in each group, 6 on the investigational product and 2 on placebo. Subjects will be randomized (3:1) to receive a single intravenous injection of BAT2022 for Injection or 5% glucose injection. Sentinel dosing will be performed for subjects in each group.Two subjects in each group who have received the first dose will be randomized (1:1) to either the test group or placebo group. After observation for 24 h and the drug is safe and well tolerated, the remaining subjects in this group will be randomized (5:1) to either the test group or placebo group.
Study NCT05020145 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2 (Tozinameran)
Description: Covid-19 Vaccine
Study NCT05215691 — intervention group
Intervention type: PROCEDURE
Intervention: Group I: TAPA block
Description: Postoperative analgesia will be provided with peripheral nerve block (TAPA)
Study NCT05215691 — intervention group
Intervention type: PROCEDURE
Intervention: Group II: IV Morphine
Description: Postoperative analgesia will be provided with opioids
Study NCT04709458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-2400
Description: Hematopoietic stem cells transplantation
Study NCT06273618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Micro-Learning
Description: Micro-Learning involves a series of 5-10 minute interactive, gamified learning exercises delivered to smart-phones (or computers) to reinforce and augment knowledge and promote attitudes and behavior to promote children's wellbeing.
Study NCT05399901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Description: Active exercises of the pelvic floor muscles and verbal instructions and EMG Biofeedback
Study NCT05399901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: M-mode US biofeedback
Description: Active exercises of the pelvic floor muscles and verbal instructions and M-mode Ultrasound Biofeedback
Study NCT04977570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA1805 tablets
Description: Oral tablets of SYHA1805 with three pre-designed doses
Study NCT04977570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets of placebo with matching doses
Study NCT05758805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mini-invasive esophagoscopy
Description: mini-invasive esophagoscopy assessment of esophageal thermal injury (ETI) after an AF ablation session in an HP-SD setting, and with a tip CF sensing ablation catheter
Study NCT05758805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP-SD AF ablation by a CF sensing catheter
Description: AF ablation session in an HP-SD setting and with a tip CF sensing ablation catheter
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given orally (PO)
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study NCT05238831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given by injection
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Description: Given phesgo SC
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given subcutaneously (SC)
Study NCT05238831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given SC
Study NCT05238831 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given intravenously (IV)
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Given IV
Study NCT05238831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study NCT05204069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Instillation of cyclopentolate
Description: Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
Study NCT05204069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instillation of cyclopentolate
Description: Instillation of cyclopentolate of 3 drops of cyclopentolate at t0',t5' and t10' with to induce a certain level of cycloplegia and evaluate manifest refraction at t45' using the RetinoMax Device.
Study NCT04051918 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Piano Training
Description: Cognitive training via music learning
Study NCT04051918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Piano Training
Description: Cognitive training via music learning
Study NCT05911178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-UCB-J
Description: PET tracer binding to SV2A protein, used to study synaptic vesicle density.
Study NCT05911178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-DPA-714
Description: PET tracer binding to TSPO protein, used to study microglial activation.
Study NCT05911178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]-RO-948
Description: PET tracer binding to tau protein, used to study the topography of tau deposition.
Study NCT05911178 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [11C]-PiB
Description: PET tracer binding to Aβ40 and Aβ42 fibrils and insoluble plaques containing the aforementioned Aß peptides, used to study the topography of amyloid deposition.
Study NCT01028872 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intraocular lens
Study NCT01028872 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Study NCT06199895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Polymeric Micelles for Injection
Description: 300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.
Study NCT04593823 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Furoscix Infusor
Description: Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.
Study NCT05075512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib, fulvestrant
Description: anlotinib: 12 mg once daily on days 1-14, repeated every 21 days; fulvestrant: 500 mg on days 1 and 15 of cycle one, and then on day one of each subsequent 28 days cycle
Study NCT04773925 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness counseling
Description: Subjects three 60-minute mindfulness counseling sessions with a certified Mind-Body Counselor who has a degree in Social Work in the department of Integrative Medicine. The mindfulness sessions will be conducted entirely via telemedicine. The initial consultation will consist of a 60-minute individual session. The next session will be a group visit (plan for 5 subjects per group) lasting 60 minutes, which will be scheduled for 2 weeks after the initial session. The third session will be another 60-minute group session, which will be scheduled for 6 weeks after the initial session.
Study NCT06456489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days
Study NCT06456489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solumedrol
Description: 125 mg methylprednisolone intravenous pulse on 2 consecutive days
Study NCT06410417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shorten abstinence time
Description: In the experimental group, male ejaculates once on human chorionic gonadotropin trigger day, and can be ejaculated on the second day if ejaculates fail.
Study NCT06494618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial Extracorporeal Shockwave Therapy
Description: 1500 pulses, 4 hertz, 2 bar radial extracorporeal shockwave therapy targeted muscle belly for botulinum toxin injected lower extremity muscle groups. 3 sessions were planned once a week, starting from first week after injection.
Study NCT05418959 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: DermTech PLA noninvasive adhesive biopsy
Description: The clinician will firmly press the DermTech noninvasive adhesive on the lesion and use their thumb to make five circular motions on the lesion. The adhesive patch will then be pulled off of the area. This will be repeated for an additional three patches.
Study NCT05420142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
Study NCT05420142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey
Description: The intervention will assess the effects of three difference varieties of plant-based protein and fibre supplements on net peripheral amino acid appearance in blood compared to whey protein with matched fibre content as a control arm.
Study NCT05319262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pink noise exposure
Description: Continuous pink noise sound exposure at 45 dBA, throughout the whole night
Study NCT05319262 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Traffic noise
Description: 120 traffic noise events (40 each of road, rail and aircraft), introduced at maximum sound pressure levels ranging between 45-65 dB LAS.max.
Study NCT05701904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local mechanical vibration
Description: Before the injection, local mechanical vibration will be applied for 3 minutes with a vibration device to the deltoid muscle where the injection will be made, and then the vaccine will be given. The vibration device to be used is suitable for contact with the skin and provides 6000 rotations per minute with vibration.
Study NCT05701904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shotblocker group
Description: It is a U-shaped device with skin contact points on the shotblocker and an opening in the middle for injection (Tugrul, Celik, and Khorshid 2017). The Shotblocker will be placed on the skin surface just before inserting the needle and gently pressed with the fingertips, and the vaccine will be administered immediately afterwards. After removing the needle, the shotblocker will be removed.
Study NCT05502822 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High definition transcranial alternating current stimulation
Description: tACS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.
Study NCT05502822 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham high definition transcranial alternating current stimulation
Description: . In the sham condition, 6-Hz tACS was delivered only during the ramp-up and ramp-down periods (30 s); no current was delivered during the 30-minute intervention.
Study NCT06411509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TC plus active rTMS
Description: The rTMS intervention is performed using a MagPro X100 by MagVenture with a water-cooled figure-of-eight coil. Before the treatment session, the resting motor threshold of the left abductor pollicis brevis is determined. The rMT is defined as the minimum intensity which produces five motor evoked potential responses of at least 50 μV in 10 trials at rest. A protocol of 1 Hz rTMS at 80% of RMT is applied over the frontal area of the right DLPFC. The coil position is localized using a frameless stereotactic neuronavigation system (TMS-Navigator, Localite GmbH, Bonn, Germany). Participants receive only three sessions of TC per week without rTMS during in the week 1 and 2, and the TC potocol is same as the TC-alone group. Participants receive daily rTMS (30 minutes) for 5 days a week combined with three sessions of TC in the last 2 weeks. Active rTMS deliveres at 1 Hz for 30 min (1800 pulses per session) with the intensity of 80% rMT.
Study NCT06411509 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Tai Chi plus sham rTMS
Description: Sham rTMS is administrated the same procedures as the active rTMS but with low intensity of 20% rMT to elicit similar skin sensations and sounds. The TC protocol in this group is the same as the TC-alone group.
Study NCT06411509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TC-alone
Description: Participants in the TC-alone group attend a simplified Yang style 8-Form Easy TC training program in a group format. Each session lasts for 60 minutes and are conducted three times per week over a period of four weeks. In the first session, the certified TC instructor explains the exercise theory and procedures. The remaining sessions includes 5 to 10 minutes warm-up and a review of TC principles, 45 minutes meditative movements, and 5 to 10 minutes cool-down
Study NCT06411509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity physical exercise
Description: To achieve the same exercise volume with TC-alone group, participants in the low-intensity physical exercise control group attend a four-week exercise training in group format. Exercise sessions are 60 minutes with three times per week. Each exercise session consists of 5 to 10 minutes warm-up, 45 minutes of aerobic training, and a 5 to 10 minutes cool-down.
Study NCT05838690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Intubation Safety (PINS) Bundle
Description: The Personalized Intubation Safety (PINS) Bundle addresses 5 core domains that are individualized to the patient to develop a prospective, personalized and comprehensive multidisciplinary intubation plan: (1) patient risk assessment; (2) treatment threshold for intubation; (3) premedication (promoting paralytic premedication); (4) equipment (promoting video laryngoscope); (5) provider selection and escalation plan
Study NCT05021471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biofeedback
Description: Twenty nine (29) patients will be treated stretching of hamstring with pressure biofeedback.
Study NCT05021471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hamstrings stretching
Description: Twenty nine (29) patients will be treated stretching of hamstring without pressure biofeedback.
Study NCT06406166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifei Xiaoji Wan
Description: The Lifei Xiaoji Wan consists of ginseng, blackhead, rhubarb, aster, forehu, and thin on
Study NCT06406166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment with Western medicine
Description: Conventional treatment with Western medicine
Study NCT05753540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Multiwave locked system laser therapy
Study NCT05753540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham laser therapy
Description: Sham laser therapy
Study NCT06234176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised psychomotor therapy
Description: The content of the sessions will be personalised and determined solely by a qualified psychomotor therapist in charge of the patient, based on each participant's individual psychomotor profile, as determined from the initial assessment.~The 12 sessions will take place with the same PT in a dedicated room at the centre where the patient is being treated. The sessions will consist of a range of playful static and dynamic body exercises, including exercises for emotional and tonic regulation, tonic-postural adaptation, and perceptual-motor adaptation.~Not all participants in the GP group will have the same progression, nature or frequency of exercises over the 12 sessions.~The study only allows for individual treatment. Other therapeutic approaches such as balneotherapy sessions, animal mediation, adapted physical activity programmes or targeted relaxation programmes are not permitted.~During each session, the participant will be required to complete the Duke health profile.